In the COVID- cohort 17 patients had no increase or change in vasopressor use, 1 individual having no change in vasopressor dose, and 1 individual had a decrease in vasopressor dose following ATA onset. In the COVID+ cohort, 11 individuals were not on a vasopressor and did not require the addition of a vasopressor, 2 individuals had no change in vasopressor dose, 17 individuals saw an increasing vasopressor requirement, 1 individual was taken off vasopressors after ATA onset, and 1 individual was taken off vasopressors after DCCV following ATA onset.